Alcon (ALC) reported $2.7 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.1%. EPS of $0.78 for the same period compares to $0.72 a year ago.
The reported revenue represents a surprise of -0.2% over the Zacks Consensus Estimate of $2.71 billion. With the consensus EPS estimate being $0.79, the EPS surprise was -0.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Total Surgical- Equipment/other: $277 million compared to the $277.54 million average estimate based on four analysts. The reported number represents a change of +21% year over year.
- Net Sales- Total Surgical- Implantables: $474 million versus $482.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Net Sales- Total Surgical: $1.55 billion compared to the $1.56 billion average estimate based on four analysts. The reported number represents a change of +8.6% year over year.
- Net Sales- Total Vision care: $1.16 billion versus the four-analyst average estimate of $1.15 billion. The reported number represents a year-over-year change of +9.8%.
- Net Sales- Total Surgical- Consumables: $794 million versus the four-analyst average estimate of $796.13 million. The reported number represents a year-over-year change of +7.6%.
- Net Sales- Total Vision Care- Contact lenses: $683 million compared to the $687.14 million average estimate based on four analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- Total Vision Care- Ocular health: $474 million compared to the $462.7 million average estimate based on four analysts. The reported number represents a change of +13.9% year over year.
- Net Sales and other revenues- Other revenues: $16 million versus $26.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -36% change.
- Net Sales and other revenues- Net Sales: $2.7 billion versus $2.7 billion estimated by three analysts on average.
View all Key Company Metrics for Alcon here>>>
Shares of Alcon have returned +2.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
